Published in J Clin Psychiatry on January 01, 2005
Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2011) 1.41
First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry (2010) 1.25
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry (2015) 1.22
Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 1.18
Revisiting thyroid hormones in schizophrenia. J Thyroid Res (2012) 0.83
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol (2014) 0.82
Thyroid dysfunction during treatment with atypical antipsychotics. J Clin Psychiatry (2005) 0.82
Thyroid dysfunction in major psychiatric disorders in a hospital based sample. Indian J Med Res (2013) 0.80
Thyroid axis function after in-patient treatment of acute psychosis with antipsychotics: a naturalistic study. BMC Psychiatry (2014) 0.78
Intoxication after extreme oral overdose of quetiapine to attempt suicide: pharmacological concerns of side effects. Case Rep Med (2010) 0.76
Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. Bipolar Disord (2016) 0.75
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry (2007) 2.26
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia. Synapse (2011) 1.43
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacol (2003) 1.37
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry (2002) 1.17
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res (2011) 1.16
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res (2011) 1.16
Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry (2008) 1.14
Suicide brain is associated with decreased expression of neurotrophins. Biol Psychiatry (2005) 1.13
Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol (2008) 1.12
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. J Nerv Ment Dis (2003) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 1.07
The heterogeneity of schizophrenia in disease states. Schizophr Res (2004) 1.04
[(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. Am J Psychiatry (2002) 1.03
Postmortem brain tissue of depressed suicides reveals increased Gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase. J Neurosci (2008) 1.01
Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry (2010) 1.00
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry (2004) 0.99
Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide. Biol Psychiatry (2008) 0.99
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology (2005) 0.98
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q (2006) 0.97
Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry (2006) 0.97
Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry (2012) 0.95
Decreased catalytic activity and expression of protein kinase C isozymes in teenage suicide victims: a postmortem brain study. Arch Gen Psychiatry (2004) 0.95
Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology (2002) 0.94
Differential and brain region-specific regulation of Rap-1 and Epac in depressed suicide victims. Arch Gen Psychiatry (2006) 0.94
Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol (2009) 0.94
Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus. Int J Neuropsychopharmacol (2006) 0.94
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc (2009) 0.93
mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims. Neuropsychopharmacology (2002) 0.93
Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. J Psychiatr Res (2003) 0.92
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 0.92
Sexuality and schizophrenia: a review. Schizophr Bull (2004) 0.92
Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull (2006) 0.92
Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. Neuropsychopharmacology (2007) 0.91
First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs (2005) 0.91
Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology (2005) 0.91
Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res (2008) 0.90
Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. J Psychiatr Res (2004) 0.90
Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2009) 0.90
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. Stat Med (2005) 0.88
Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis. Synapse (2005) 0.88
Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry (2006) 0.88
Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse (2009) 0.87
Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients. Bipolar Disord (2008) 0.87
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Compr Psychiatry (2009) 0.86
Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol (2004) 0.85
Fatty acid composition of the postmortem prefrontal cortex of adolescent male and female suicide victims. Prostaglandins Leukot Essent Fatty Acids (2008) 0.85
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res (2008) 0.85
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry (2011) 0.85
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin (2011) 0.84
5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims. Open Neuropsychopharmacol J (2008) 0.84
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis. Neuropsychiatr Dis Treat (2012) 0.84
Mitochondria in the striatum of subjects with schizophrenia. World J Biol Psychiatry (2010) 0.83
Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response. Synapse (2011) 0.83
Circumstances of suicide among individuals with schizophrenia. Schizophr Res (2002) 0.83
GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. Neurochem Res (2008) 0.83
Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia. Synapse (2008) 0.83
Reaching for wellness in schizophrenia. Psychiatr Clin North Am (2007) 0.83
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology (2010) 0.83
Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol (2006) 0.83
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry (2011) 0.82
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry (2004) 0.81
Aberrant extracellular signal-regulated kinase (ERK) 5 signaling in hippocampus of suicide subjects. Neuropsychopharmacology (2007) 0.81
Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry (2003) 0.80
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol (2003) 0.80
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res (2011) 0.80
Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry (2004) 0.80
Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology. IRB (2011) 0.79
Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract (2003) 0.79
Clozapine treatment in patients with prior substance abuse. Can J Psychiatry (2003) 0.79
Synaptic differences in the patch matrix compartments of subjects with schizophrenia: a postmortem ultrastructural study of the striatum. Neurobiol Dis (2005) 0.79
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry (2008) 0.78
Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacol (2004) 0.78
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine. J Clin Psychiatry (2003) 0.76
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry (2012) 0.76
Evaluating sexual function in patients with treatment-resistant schizophrenia. Schizophr Res (2003) 0.76
The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol (2005) 0.76
Challenge to atypical antipsychotic drug effect on cognition. Am J Psychiatry (2007) 0.76
Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ (2012) 0.76
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. J Clin Psychopharmacol (2010) 0.76
Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. J Neuropsychiatry Clin Neurosci (2005) 0.76
Comparison of clozapine response for inpatients in the research setting versus routine clinical practice. Psychiatr Q (2008) 0.75
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2013) 0.75
Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics. J Clin Psychiatry (2009) 0.75
Protecting confidentiality in human research. Am J Psychiatry (2013) 0.75
Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. CNS Spectr (2006) 0.75
Cortisol response to buspirone in extended abstinent alcoholics. Alcohol Alcohol (2004) 0.75
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis. J Clin Psychopharmacol (2007) 0.75